Topotecan liposomal - Spectrum Pharmaceuticals

Drug Profile

Topotecan liposomal - Spectrum Pharmaceuticals

Alternative Names: Brakiva; INX-0076; Liposomal topotecan; Optisomal topotecan; Sphingosome-encapsulated topotecan; Topotecan liposome injection; Topotecan-TCS

Latest Information Update: 18 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inex Pharmaceuticals Corporation
  • Developer Spectrum Pharmaceuticals
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Ovarian cancer; Small cell lung cancer

Most Recent Events

  • 18 May 2016 No recent reports of development identified - Phase-I for Small cell lung cancer (Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 18 May 2016 No recent reports on development identified - Phase-I for Ovarian cancer (Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 23 Oct 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top